Novo Nordisk's cash tender offer to acquire all outstanding Dicerna shares no longer includes CEO Douglas Fambrough's personal shares, according to documents amending the original filing to the US Securities and Exchange Commission (SEC).
Fambrough and Marc Kozin, a member of Dicerna's board of directors, have decided to withdraw their tender of Dicerna shares otherwise included in Novo Nordisk's offer to pay USD 38.25 per share, equating to a price of USD 3.3bn for the US-based biotech firm.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.